Researchers tested a new cold plasma technology combined with an existing anti-parasite drug (amphotericin B) against Leishmania parasites that cause skin infections. The cold plasma, which contains reactive chemicals, killed the parasites by triggering their programmed cell death (apoptosis) while causing minimal harm to human immune cells. When combined with the medication, the treatment was even more effective, potentially allowing lower drug doses with fewer side effects.